Date: 2014-06-24
Type of information: Fundraising
Company: Fab’entech (France)
Investors: Auriga Partners (France), R2V (France), Rhône-Alpes Création (France), Sigma Gestion (France) and several companies investing on a personal level.
Amount: €5 million
Funding type: fundraising
Planned used: Fab’entech is focused on specific polyclonal immunoglobulins against emerging infectious diseases. This biopharmaceutical company founded in Lyon, France, is aiming to become the global benchmark in anti-infectious passive immunotherapeutic solutions. The company is developing an extensive portfolio of polyclonal immunoglobulins, centred on a first product aimed at fighting infections caused by H5N1 avian flu. Fab’entech relies on a proven and recognised technology stemming from Sanofi Pasteur – the vaccines division of Sanofi – and in close collaboration with its historical partner, the INSERM – Jean Mérieux BSL4 Laboratory. The company develops therapeutic solutions against diseases such as avian flu H5N1 and H7N9, Crimean-Congo hemorrhagic fever (CCHF), the Ebola and Lassa viruses, encephalitis and pneumonias linked to the Nipahand Hendra viruses, respiratory diseases caused by coronaviruses (MERS-Cov and SARS), and also bioterrorist threats. The company is firmly rooted in Lyon for its R&D and production activities. In contrast, the markets targeted by Fab’entech are essentially international, in all countries, both industrialised and emerging, that are obliged to face the rising risks of pandemics and emerging infectious diseases. This fund raising operation aims to help the company to step up its international expansion, especially in Australia and Asia, extend its product portfolio to cover a wide range of pathogens and to build its own production site in Lyon.
Others: * On June 24, 2014, Fab’entech, the specialist in specific polyclonal immunoglobulins againstemerging infectious diseases, announces the completion of €5 millionin fund raising with Auriga Partners , R2V,Rhône-Alpes Création, Sigma Gestion and several companies investing on a personal level. In addition to representatives of financial investors, the company’s supervisory board is to welcome Mr Jacques-François Martin, who was notably CEO of Pasteur Merieux Connaught (now Sanofi Pasteur) and Chiron Vaccines (now Novartis), as Chairman of the Supervisory Board, and Mr Albert Saporta, former Chairman and CEO of Stallergènes.
Therapeutic area: Infectious diseases
